Soleno Therapeutics (SLNO) Common Equity: 2013-2018
Historic Common Equity for Soleno Therapeutics (SLNO) over the last 6 years, with Dec 2018 value amounting to $30.4 million.
- Soleno Therapeutics' Common Equity rose 4.79% to $14.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $14.9 million, marking a year-over-year increase of 4.79%. This contributed to the annual value of $30.4 million for FY2018, which is 13.41% up from last year.
- Soleno Therapeutics' Common Equity amounted to $30.4 million in FY2018, which was up 13.41% from $26.8 million recorded in FY2017.
- In the past 5 years, Soleno Therapeutics' Common Equity ranged from a high of $30.4 million in FY2018 and a low of -$11.2 million during FY2014.
- Moreover, its 3-year median value for Common Equity was $26.8 million (2017), whereas its average is $20.2 million.
- Data for Soleno Therapeutics' Common Equity shows a peak YoY spiked of 680.65% (in 2017) over the last 5 years.
- Yearly analysis of 5 years shows Soleno Therapeutics' Common Equity stood at -$11.2 million in 2014, then surged by 128.81% to $3.2 million in 2015, then rose by 6.56% to $3.4 million in 2016, then spiked by 680.65% to $26.8 million in 2017, then grew by 13.41% to $30.4 million in 2018.